Get the Stockscreener App
1.43
2.72%
-0.04
After Hours:
1.44
0.01
+0.70%
Maxcyte Inc stock is traded at $1.43, with a volume of 454.55K.
It is down -2.72% in the last 24 hours and down -7.14% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$1.47
Open:
$1.47
24h Volume:
454.55K
Relative Volume:
0.52
Market Cap:
$152.54M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-4.2059
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
-7.74%
1M Performance:
-7.14%
6M Performance:
-36.44%
1Y Performance:
-68.71%
1-Day Range:
$1.43
$1.49
1-Week Range:
$1.43
$1.59
52-Week Range:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.43 | 156.81M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - MSN
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen - Defense World
How strong is MaxCyte Inc. stock balance sheet2025 Performance Recap & Community Driven Trade Alerts - ulpravda.ru
Is MaxCyte Inc. stock attractive after correctionTrail vs Road Selection & walk-ready comfort choices - ulpravda.ru
Will MaxCyte Inc. stock gain from government policiesTrade Volume Report & Entry and Exit Point Strategies - ulpravda.ru
Why MaxCyte Inc. stock remains undervaluedJuly 2025 Trends & Verified Short-Term Trading Plans - ulpravda.ru
Will MaxCyte Inc. stock rally after Fed decisionsStop Loss & Weekly Market Pulse Alerts - ulpravda.ru
Aug Outlook: Will MaxCyte Inc. stock gain from government policiesWeekly Trade Report & Risk Managed Investment Entry Signals - ulpravda.ru
How sustainable is MaxCyte Inc. stock dividend payout2025 Technical Patterns & Weekly Breakout Stock Alerts - ulpravda.ru
Will MaxCyte Inc. stock outperform value stocksWeekly Gains Report & Free Community Supported Trade Ideas - ulpravda.ru
Downgrade Watch: Why retail investors pile into MaxCyte Inc. stockQuarterly Profit Report & Accurate Buy Signal Notifications - ulpravda.ru
MaxCyte (NASDAQ:MXCT) Shares Up 0.7% – Time to Buy? - Defense World
Bear Alert: How strong is MaxCyte Inc stock balance sheet2025 Market Sentiment & Real-Time Volume Analysis - moha.gov.vn
Aug Patterns: Will MaxCyte Inc stock gain from government policiesInflation Watch & Safe Capital Growth Stock Tips - moha.gov.vn
MaxCyte, Inc.Common Stock (NQ: MXCT - FinancialContent
Will MaxCyte Inc. stock attract more institutional investorsBlue Chip Stock Analysis & Free Trading Psychology Coaching - ulpravda.ru
Will MaxCyte Inc. stock deliver strong dividend growth2026 world cup usa national team group stage defensive leaders pressing system tactical prediction guide - ulpravda.ru
MaxCyte eyes growth in cell engineering for 2026 - Traders Union
MXCT’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
MaxCyte advances GMP process with KSQ partnership - Traders Union
Activity Recap: Why GIGGU stock appeals to dividend seekersTrade Entry Report & Smart Allocation Stock Reports - moha.gov.vn
Will MaxCyte Inc. stock benefit from sector rotationShare Buyback & Capital Efficient Trade Techniques - Улправда
Why retail investors pile into MaxCyte Inc. stock2025 Price Targets & Fast Entry Momentum Trade Alerts - Улправда
Is MaxCyte Inc. stock a bargain at current levels2025 Major Catalysts & Free Long-Term Investment Growth Plans - Улправда
Stock Recap: How buybacks impact MaxCyte Inc. stock valueJuly 2025 Summary & Verified Technical Trade Signals - DonanımHaber
MaxCyte, Inc.(NasdaqGS: MXCT) dropped from NASDAQ Biotechnology Index - MarketScreener
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
William Blair Downgrades MaxCyte (MXCT) - MSN
Prepare Yourself for Liftoff: MaxCyte Inc (MXCT) - setenews.com
Healthy Upside Potential: MaxCyte Inc (MXCT) - setenews.com
Mirabella Financial Services LLP Has $14.39 Million Stock Position in MaxCyte, Inc. $MXCT - MarketBeat
How MaxCyte Inc. (MYE0) stock compares with market leadersWeekly Stock Report & Smart Swing Trading Techniques - Newser
Is MaxCyte Inc. (MYE0) stock attractive post correction2025 Top Gainers & Daily Price Action Insights - Newser
Can MaxCyte Inc. (MYE0) stock stage a strong rebound this quarterJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser
Is MaxCyte Inc. stock attractive for ETFsTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Why analysts recommend MaxCyte Inc. (MYE0) stockJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Is MaxCyte Inc. (MYE0) stock dividend growth reliableAnalyst Upgrade & Stepwise Trade Execution Plans - Newser
MaxCyte drives CAR T manufacturing optimization using ExPERT system - Traders Union
Dividend Watch: Why Clearway Energy Inc. (NY4B) stock is upgraded to buyJuly 2025 Volume & Verified Technical Signals - BỘ NỘI VỤ
MaxCyte (MXCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Morningstar
The time has not yet come to remove your chips from the table: MaxCyte Inc (MXCT) - setenews.com
MaxCyte aims to optimize CAR T manufacturing with ExPERT system - Traders Union
MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
MXCT SEC FilingsMaxcyte 10-K, 10-Q, 8-K Forms - Stock Titan
What drives MaxCyte Inc MYE0 stock priceRSI Overbought/Oversold & Daily Tips From Top Market Analysts - earlytimes.in
How MaxCyte Inc. (MYE0) stock reacts to fiscal policiesJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Can MaxCyte Inc. (MYE0) stock reach $200 price target2025 Major Catalysts & Weekly High Return Opportunities - newser.com
MaxCyte explores electroporation's role in cell therapy innovation - Traders Union
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.31%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):